secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001213900-25-106398
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada prices $100M underwritten offering of common stock and pre-funded warrants at $2.20/share
--------------------------------------------------------------------------------

- Priced 40.1M shares of common stock at $2.20/share and pre-funded warrants for 5.3M shares at $2.199/warrant.
- Gross proceeds of ~$100M; net proceeds ~$100M after expenses, expected closing Nov 5, 2025.
- Investors include Janus Henderson, Ferring Ventures, Squadron Capital, Marshall Wace, Spruce Street, OrbiMed, Columbia Threadneedle, Driehaus.
- Company insiders (CEO, CFO, board members) purchasing ~$2.6M in shares at same price.
- Proceeds for working capital, clinical studies, product development, and potential acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025106398/0001213900-25-106398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025106398/ea0263855-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-106398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer